Compare LAKE & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAKE | FATE |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.0M | 125.6M |
| IPO Year | 2013 | 2013 |
| Metric | LAKE | FATE |
|---|---|---|
| Price | $11.24 | $2.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $15.33 | $4.10 |
| AVG Volume (30 Days) | 52.5K | ★ 1.8M |
| Earning Date | 04-16-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $192,648,000.00 | $6,646,000.00 |
| Revenue This Year | $10.88 | N/A |
| Revenue Next Year | $10.71 | N/A |
| P/E Ratio | $281.25 | ★ N/A |
| Revenue Growth | ★ 15.21 | N/A |
| 52 Week Low | $7.15 | $0.93 |
| 52 Week High | $18.00 | $3.23 |
| Indicator | LAKE | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 44.20 |
| Support Level | $10.46 | $2.25 |
| Resistance Level | $11.55 | $2.88 |
| Average True Range (ATR) | 0.50 | 0.18 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 16.47 | 27.69 |
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe, and Other Foreign. It generates the majority of its revenue from the United States.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.